Kyntra Bio, Inc.
Records under this name other than the patents Kyntra Bio, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 19 patents it holds.
Showing 1 to 6 of 6 · Back to Kyntra Bio, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,713,986 | Compounds and Methods for Treatment of Chemotherapy-Induced Anemia Term ended Term ended Jun 15, 2026 · High confidence | Term ended | Term ended Jun 15, 2026 | High confidence |
| US 7,629,357 | Novel Nitrogen-Containing Heteroaryl Compounds and Methods of Use Thereof Term ended Term ended Jun 8, 2026 · Medium confidence | Term ended | Term ended Jun 8, 2026 | Medium confidence |
| US 7,618,940 | Fat Regulation Term ended Term ended Apr 3, 2026 · High confidence | Term ended | Term ended Apr 3, 2026 | High confidence |
| US 9,000,006 | Novel Thienopyridine Compounds, and Methods of Use Thereof Term ended Term ended Mar 2, 2026 · Medium confidence | Term ended | Term ended Mar 2, 2026 | Medium confidence |
| US 8,017,625 | Novel Nitrogen-Containing Heteroaryl Compounds and Methods of Use Thereof Term ended Term ended Mar 1, 2026 · High confidence | Term ended | Term ended Mar 1, 2026 | High confidence |
| 19/589,689 | [(4-Hydroxy-1-Methyl-7-Phenoxyisoquinoline-3-Carbonyl)AMINO]ACETIC Acid (ROXADUSTAT) for the Treatment of Anemia in Subjects with Myelodysplastic Syndrome (MDS) held by Fibrogen International (Hong Kong) Limited Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. |